Suggested Remit: To appraise the clinical and cost effectiveness of rivogenlecleucel within its marketing authorisation for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant.
Status In progress
Process STA 2018
ID number 1601

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
24 January 2020 In progress, Topic is in progress
13 May 2019 (10:00) Scoping workshop (Manchester)
20 March 2019 - 17 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance